Table 5 Results of one-way and two-way sensitivity analyses
One-way | Two-way | |||
|---|---|---|---|---|
Parameters | Range for sensitivity analysis | ICER (US$ per DALY averted) | Parameters with range for sensitivity analysis | ICER (US$ per DALY averted) |
Vaccine effectiveness | 80% | 93 | Vaccine effectiveness (60–80%) + Vaccine utilization (10–66%) | 88 |
60% | 169 | 663 | ||
Vaccine utilization | 66% | 90 | Vaccine effectiveness (60–80%) + Risk of perinatal transmission (HBeAg −) (2%–29%) | CS |
10% | 625 | 475 | ||
Risk of perinatal transmission (HBeAg −) | 29% | CS | Vaccine effectiveness (60–80%) + Prevalence of HBV infection among mothers (2.5–10%) (10–66%) | CS |
2% | 373 | 421 | ||
Prevalence of HBV infection among mothers | 10% | CS | Vaccine effectiveness (60%–80%) + Cost of medical care (from no cost to twice the cost of morbid states) (10–66%) | CS |
2.5% | 328 | 207 | ||
Cost of medical care | Twice the cost | CS | Vaccine effectiveness (60–80%) + Average cost per vaccinated child ($0.5–1.0) (10–66%) | 13 |
No cost | 158 | 262 | ||
Average cost per vaccinated child | $0.5 | 29 | Vaccine effectiveness (60–80%) + Risk of perinatal transmission (HBeAg +) (14–56%) | 32 |
$1.0 | 195 | 214 | ||
Risk of prinatal transmission (HBeAg +) | 56% | 51 | Vaccine effectiveness (60–80%) + Prevalence of HBeAg in pregnant women (5–25%) (10–66%) | 40 |
14% | 156 | 202 | ||
Prevalence of HBeAg in pregnant women | 25% | 59 | Vaccine effectiveness (60–80%) + Transition prob. of CAH to inactive carrier state (30–70%) (10–66%) | 35 |
5% | 146 | 174 | ||
Transition prob. of CAH to inactive carrier state | 30% | 60 | Â | Â |
70% | 124 | Â | Â | |